NVO Overview
Upcoming Projects (NVO)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (NVO)
-
Obesity/Diabetes Series-December 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Dec 20, 2024 at 02:00 PM EST -
Obesity/Diabetes Series-December 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Dec 19, 2024 at 05:00 PM EST -
A Second Look: Discussing the topline results from the SURMOUNT-5 phase 3b head-to-head weight loss trial of Zepbound (tirzepatide) compared to Wegovy (semaglutide).
Tickers: LLY, NVO
Executed On: Dec 18, 2024 at 06:00 PM EST -
Discussing the topline results from the SURMOUNT-5 phase 3b head-to-head weight loss trial of Zepbound (tirzepatide) compared to Wegovy (semaglutide).
Tickers: NVO, LLY
Executed On: Dec 17, 2024 at 12:30 PM EST -
A Third Look: Discussing the results from part 1 of the ongoing ESSENCE trial of semaglutide at 2.4 mg for adult patients with MASH and moderate to advanced liver fibrosis (stage 2 or 3)
Ticker: NVO
Executed On: Dec 10, 2024 at 05:30 PM EST -
A Second Look: Discussing the results from part 1 of the ongoing ESSENCE trial of semaglutide at 2.4 mg for adult patients with MASH and moderate to advanced liver fibrosis (stage 2 or 3)
Ticker: NVO
Executed On: Dec 09, 2024 at 09:30 AM EST -
A Second Opinion: Delving into the data on amycretin in patients with obesity and diabetes which was presented at EASD 2024
Ticker: NVO
Executed On: Dec 05, 2024 at 10:45 AM EST -
Discussing the results from part 1 of the ongoing ESSENCE trial of semaglutide at 2.4 mg for adult patients with MASH and moderate to advanced liver fibrosis (stage 2 or 3)
Ticker: NVO
Executed On: Dec 03, 2024 at 02:00 PM EST -
Obesity/Diabetes Series-November 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Nov 26, 2024 at 08:30 AM EST -
Obesity/Diabetes Series-November 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Nov 22, 2024 at 05:00 PM EST -
Second View: Discussing Novo Nordisk's recent Phase 2 trial results on Monolunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, in the treatment of obesity.
Ticker: NVO
Executed On: Nov 21, 2024 at 03:30 PM EST -
Obesity/Diabetes Series-November 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Nov 21, 2024 at 10:00 AM EST -
A Third Look: Discussing the impacts of GLP-1 weight loss options on patients frequency of PCP visits, additional diagnosis, and the use and popularity of CGMs
Tickers: NVO, LLY, ABT
Executed On: Nov 15, 2024 at 11:00 AM EST -
A Second Look: Discussing the impacts of GLP-1 weight loss options on patients frequency of PCP visits, additional diagnosis, and the use and popularity of CGMs
Tickers: NVO, LLY, ABT
Executed On: Nov 15, 2024 at 10:00 AM EST -
Discussing the impacts of GLP-1 weight loss options on patients frequency of PCP visits, additional diagnosis, and the use and popularity of CGMs
Tickers: NVO, LLY, ABT
Executed On: Nov 14, 2024 at 06:00 PM EST -
Discussing Novo Nordisk's recent Phase 2 trial results on Monolunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist, in the treatment of obesity.
Ticker: NVO
Executed On: Nov 08, 2024 at 04:00 PM EST -
Delving into the data on amycretin in patients with obesity and diabetes which was presented at EASD 2024
Ticker: NVO
Executed On: Nov 07, 2024 at 06:00 PM EST -
Third View: Discussing Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
Tickers: NVO, LLY
Executed On: Nov 06, 2024 at 04:00 PM EST -
Second View: Discussing Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
Tickers: NVO, LLY
Executed On: Nov 04, 2024 at 03:00 PM EST -
Discussing Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.
Tickers: NVO, LLY
Executed On: Oct 30, 2024 at 12:30 PM EDT -
A Second View: Discussing the risks of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Ticker: NVO
Executed On: Oct 24, 2024 at 08:00 AM EDT -
A Third Look: Discussing the potential of semaglutide for treating hidradenitis suppurativa (HS) in obese or overweight patients and the HS results from the STEP 5 trial of semaglutide.
Ticker: NVO
Executed On: Oct 22, 2024 at 12:00 PM EDT -
Obesity/Diabetes Series-October 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 16, 2024 at 09:30 AM EDT -
A Second Look: Discussing the potential of semaglutide for treating hidradenitis suppurativa (HS) in obese or overweight patients and the HS results from the STEP 5 trial of semaglutide.
Ticker: NVO
Executed On: Oct 16, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-October 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 11, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-October 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 10, 2024 at 05:00 PM EDT -
Discussing the potential of semaglutide for treating hidradenitis suppurativa (HS) in obese or overweight patients and the HS results from the STEP 5 trial of semaglutide.
Ticker: NVO
Executed On: Oct 09, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-October 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Oct 04, 2024 at 04:30 PM EDT -
Discussing the risks of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Ticker: NVO
Executed On: Oct 01, 2024 at 02:00 PM EDT -
Obesity/Diabetes Series-September 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 25, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-September 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 19, 2024 at 10:30 AM EDT -
Obesity/Diabetes Series-September 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Sep 13, 2024 at 01:30 PM EDT -
A Third Opinion: Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 12, 2024 at 10:30 AM EDT -
A Second Opinion: Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 06, 2024 at 09:00 AM EDT -
Discussing the potential of Semaglutide as a treatment option for heart failure based off the results from the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials.
Tickers: NVO, LLY
Executed On: Sep 04, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-August 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Aug 30, 2024 at 04:30 PM EDT -
A Third View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 30, 2024 at 11:00 AM EDT -
A Third Look: Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 21, 2024 at 04:00 PM EDT -
A Second Opinion: Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 21, 2024 at 02:00 PM EDT -
A Second View: Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 04:00 PM EDT -
Digging into the phase 2b trial of liraglutide in patients with Alzheimer's disease
Tickers: NVO, BIIB, LLY
Executed On: Aug 20, 2024 at 11:00 AM EDT -
Obesity/Diabetes Series-August 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Aug 16, 2024 at 10:00 AM EDT -
Discussing the potential of Novo Nordisk's Cannabinoid blocker, INV 202 for obesity treatment
Tickers: NVO, LLY
Executed On: Aug 15, 2024 at 09:30 AM EDT -
A fourth look discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 25, 2024 at 12:00 PM EDT -
A Third Opinion: Discussing the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 25, 2024 at 11:30 AM EDT -
A Second Opinion: Discussing the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 25, 2024 at 08:30 AM EDT -
A Third Look: Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 24, 2024 at 01:00 PM EDT -
A third look discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 23, 2024 at 05:00 PM EDT -
Obesity/Diabetes Series-July 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 22, 2024 at 05:00 PM EDT -
Obesity/Diabetes Series-July 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 19, 2024 at 04:00 PM EDT -
A Second Look: Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 18, 2024 at 02:00 PM EDT -
Discussing the results of a new observational study published in JAMA " Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity".
Tickers: LLY, NVO
Executed On: Jul 18, 2024 at 01:00 PM EDT -
Sharing your thoughts on the potential of Fractyl Health's lead drug candidate Rejuva, an adeno-associated virus (AAV)-based GLP-1 pancreatic gene therapy.
Tickers: GUTS, NVO, LLY
Executed On: Jul 16, 2024 at 10:00 AM EDT -
Obesity/Diabetes Series-July 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 12, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-July 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 11, 2024 at 01:00 PM EDT -
Obesity/Diabetes Series-July 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jul 10, 2024 at 10:00 AM EDT -
A Second Look: Discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jul 02, 2024 at 02:30 PM EDT -
Discussing how coverage, access, and pricing are evolving and being considered for GLP-1 obesity drugs, with a focus on Wegovy and Zebound.
Tickers: LLY, NVO
Executed On: Jun 27, 2024 at 03:00 PM EDT -
A Second View: Discussing the current state of GLP-1 medication compounding practices with a pharmacist
Tickers: LLY, HIMS, NVO
Executed On: Jun 27, 2024 at 07:00 AM EDT -
Obesity/Diabetes Series-June 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 25, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-June 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 21, 2024 at 08:00 AM EDT -
Discussing the current state of GLP-1 medication compounding practices with a pharmacist
Tickers: LLY, HIMS, NVO
Executed On: Jun 20, 2024 at 09:00 AM EDT -
A Third Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 13, 2024 at 03:10 PM EDT -
A Third look at the recent data from the FLOW trial and the effects of semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Ticker: NVO
Executed On: Jun 13, 2024 at 08:00 AM EDT -
A Second Opinion: Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 11, 2024 at 01:00 PM EDT -
Looking at Structure Therapeutics GLP-1 Receptor Agonist, GSBR-1290, and the results from their 12 week Phase 2a study
Tickers: GPCR, LLY, NVO
Executed On: Jun 10, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-June 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 06, 2024 at 11:00 AM EDT -
Obesity/Diabetes Series-June 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jun 06, 2024 at 09:00 AM EDT -
A second look at the recent data from the FLOW trial and the effects of semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Ticker: NVO
Executed On: May 31, 2024 at 12:00 PM EDT -
A look at the recent data from the FLOW trial and the effects of semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
Ticker: NVO
Executed On: May 31, 2024 at 11:00 AM EDT -
A Third Look: Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity with an Oncologist
Tickers: LLY, NVO
Executed On: May 30, 2024 at 08:00 AM EDT -
A Second View: Discussing the phase 3 ONWARDS trial data for Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with type 2 diabetes
Ticker: NVO
Executed On: May 24, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-May 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 24, 2024 at 01:00 PM EDT -
Obesity/Diabetes Series-May 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 24, 2024 at 12:00 PM EDT -
Discussing the phase 3 ONWARDS trial data for Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults with type 2 diabetes
Ticker: NVO
Executed On: May 21, 2024 at 10:00 AM EDT -
Obesity/Diabetes Series-May 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: May 02, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-April 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 30, 2024 at 11:00 AM EDT -
A Third Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 25, 2024 at 05:15 PM EDT -
A Second Discussion: Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 19, 2024 at 04:00 PM EDT -
A Second Look: Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Tickers: LLY, NVO
Executed On: Apr 19, 2024 at 09:00 AM EDT -
A Third Look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Ticker: NVO
Executed On: Apr 17, 2024 at 05:35 PM EDT -
Looking at the potential effects of GLP1 medications on Parkinson's Disease
Tickers: SNY, NVO, LLY
Executed On: Apr 17, 2024 at 04:30 PM EDT -
Obesity/Diabetes Series-April 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 11, 2024 at 03:00 PM EDT -
Obesity/Diabetes Series-April 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 09, 2024 at 06:00 PM EDT -
Obesity/Diabetes Series-April 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 05, 2024 at 03:00 PM EDT -
A Second Look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Ticker: NVO
Executed On: Apr 05, 2024 at 02:00 PM EDT -
Obesity/Diabetes Series-April 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 04, 2024 at 08:30 AM EDT -
Discussing the standard of care and the recent Phase 1 data presented by Novo Nordisk for their novel oral agent, amycretin
Ticker: NVO
Executed On: Mar 25, 2024 at 11:00 AM EDT -
A look at the potential of semaglutide as adjunct treatment for patients with T2D and CKD and the results from the kidney outcomes FLOW trial.
Ticker: NVO
Executed On: Mar 14, 2024 at 04:00 PM EDT -
Obesity/Diabetes Series-March 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 14, 2024 at 02:00 PM EDT -
Obesity/Diabetes Series-March 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 13, 2024 at 03:30 PM EDT -
A Second Look: Discussing the FDA approval of Wegovy® in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease.
Ticker: NVO
Executed On: Mar 13, 2024 at 11:00 AM EDT -
Discussing the FDA approval of Wegovy® in the US for cardiovascular risk reduction in people with overweight or obesity and established cardiovascular disease.
Ticker: NVO
Executed On: Mar 13, 2024 at 08:00 AM EDT -
Obesity/Diabetes Series-March 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 11, 2024 at 11:00 AM EDT -
Discussing GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes, With and Without Overweight/Obesity
Tickers: LLY, NVO
Executed On: Mar 07, 2024 at 01:40 PM EST -
Obesity/Diabetes Series-March 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 05, 2024 at 11:00 AM EST -
A Third View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Mar 04, 2024 at 06:30 PM EST -
Obesity/Diabetes Series-March 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Mar 04, 2024 at 10:00 AM EST -
A Second View: Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 29, 2024 at 10:30 AM EST -
Obesity/Diabetes Series-February 2024 (5): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 28, 2024 at 11:30 AM EST -
Obesity/Diabetes Series-February 2024 (4): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 16, 2024 at 09:00 AM EST -
Obesity/Diabetes Series-February 2024 (3): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 15, 2024 at 04:00 PM EST -
Obesity/Diabetes Series-February 2024 (2): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 12, 2024 at 12:00 PM EST -
Obesity/Diabetes Series-February 2024 (1): A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Feb 09, 2024 at 01:00 PM EST -
Delving into the phase 1 clinical trial of Amgen's MariTide for the treatment of obesity.
Tickers: AMGN, NVO, LLY
Executed On: Feb 07, 2024 at 02:00 PM EST -
A Second Opinion: Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 18, 2024 at 10:00 AM EST -
Obesity/Diabetes Series: A broad discussion on the use of GLP-1 medications for the management of obesity and type 2 diabetes
Tickers: LLY, NVO
Executed On: Jan 18, 2024 at 08:00 AM EST -
Investigating the impact of GLP-1 medications on the progression and management of diabetic retinopathy.
Tickers: LLY, NVO
Executed On: Jan 16, 2024 at 10:30 AM EST -
Looking at the potential of Altimmune's pemvidutide, a GLP-1/glucagon dual receptor agonist for patients with obesity
Tickers: ALT, LLY, NVO
Executed On: Jan 11, 2024 at 09:30 AM EST -
Discussing how payor's are strategizing reimbursement for GLP-1 drugs for the prevention of heart disease based on cardiovascular benefits shown in the SELECT trial.
Ticker: NVO
Executed On: Dec 05, 2023 at 12:00 PM EST -
A third look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 29, 2023 at 02:45 PM EST -
A second look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 22, 2023 at 12:00 PM EST -
A look at the use of GLP-1 agonists and factors affecting prescribing patterns and insurance coverage for these agents with an Endocrinologist.
Tickers: LLY, NVO
Executed On: Nov 21, 2023 at 03:00 PM EST -
A Third View: Discussing the SELECT Trial for Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes with a cardiologist
Ticker: NVO
Executed On: Nov 21, 2023 at 02:00 PM EST -
A Second Payor Perspective: Discussing how access and pricing are being considered for GLP-1 obesity drugs with a focus on Wegovy and Zebound
Tickers: LLY, NVO
Executed On: Nov 21, 2023 at 01:00 PM EST -
A Second View: Discussing the SELECT Trial for Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes with a cardiologist
Ticker: NVO
Executed On: Nov 17, 2023 at 12:00 PM EST -
Discussing the SELECT Trial for Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes with a cardiologist
Ticker: NVO
Executed On: Nov 16, 2023 at 05:00 PM EST -
A Payor Perspective: Discussing how access and pricing are being considered for GLP-1 obesity drugs with a focus on Wegovy and Zebound
Tickers: LLY, NVO
Executed On: Nov 16, 2023 at 01:00 PM EST -
A Third Opinion: Discussing the standard of care and/or the potential of semaglutide to treat chronic kidney disease and Novo Nordisk's decision to stop their semaglutide kidney outcomes trial, FLOW
Ticker: NVO
Executed On: Nov 07, 2023 at 02:00 PM EST -
A Second Opinion: Discussing the standard of care and/or the potential of semaglutide to treat chronic kidney disease and Novo Nordisk's decision to stop their semaglutide kidney outcomes trial, FLOW
Ticker: NVO
Executed On: Nov 02, 2023 at 10:00 AM EDT -
Discussing the standard of care and/or the potential of semaglutide to treat chronic kidney disease and Novo Nordisk's decision to stop their semaglutide kidney outcomes trial, FLOW
Ticker: NVO
Executed On: Nov 01, 2023 at 05:05 PM EDT -
A Third View: Discussing the GI related side effects of GLP-1 agonists
Tickers: LLY, NVO
Executed On: Oct 27, 2023 at 12:00 PM EDT -
A Second View: Discussing the GI related side effects of GLP-1 agonists
Tickers: NVO, LLY
Executed On: Oct 13, 2023 at 04:00 PM EDT -
A second look at how payers within the U.S. are strategizing the reimbursement of obesity drugs such as semaglutide and tirzepatide.
Tickers: LLY, NVO
Executed On: Oct 06, 2023 at 02:30 PM EDT -
Discussing the GI related side effects of GLP-1 agonists
Tickers: NVO, LLY
Executed On: Oct 06, 2023 at 01:00 PM EDT -
A Second Look: Discussing how US psychiatrists prescribe Wegovy to battle medication-induced weight gain
Tickers: NVO, LLY
Executed On: Aug 17, 2023 at 10:30 AM EDT -
Discussing how US psychiatrists prescribe Wegovy to battle medication-induced weight gain
Tickers: NVO, LLY
Executed On: Aug 17, 2023 at 09:45 AM EDT -
A look at how payers within the U.S. are strategizing the reimbursement of obesity drugs such as semaglutide and tirzepatide.
Tickers: LLY, NVO
Executed On: Aug 11, 2023 at 09:30 AM EDT -
A Third View: Looking into Sagimet's potential drug candidate denifanstat for the treatment of Nonalcoholic steatohepatitis (NASH)
Tickers: SGMT, NVO
Executed On: Jul 26, 2023 at 10:00 AM EDT -
Discussing the uptick in ER visits due to Ozempic (Semaglutide) use with an Emergency Medicine physician
Ticker: NVO
Executed On: Jun 29, 2023 at 02:00 PM EDT -
A third opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: Jun 06, 2023 at 04:30 PM EDT -
A second opinion: Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 11, 2023 at 01:00 PM EDT -
Understanding the Landscape of Type-2 Diabetes Treatments and the recent results from Eli Lilly's SURMOUNT-2 study for tirzepatide
Tickers: LLY, AZN, NVO
Executed On: May 10, 2023 at 06:15 PM EDT -
A second look: Digging in to the Phase 3a STEP TEEN study of once-weekly semaglutide in adolescents with obesity and the potential of Wegovy (semaglutide) in kids ages 12 through 17.
Ticker: NVO
Executed On: Apr 19, 2023 at 04:00 PM EDT -
Digging in to the Phase 3a STEP TEEN study of once-weekly semaglutide in adolescents with obesity and the potential of Wegovy (semaglutide) in kids ages 12 through 17.
Ticker: NVO
Executed On: Apr 10, 2023 at 01:45 PM EDT -
A third look at the potential of oral semaglutide in higher doses based on the results Phase IIIb PIONEER PLUS study in patients with Type 2 diabetes.
Ticker: NVO
Executed On: Apr 04, 2023 at 05:15 PM EDT -
A second look at the potential of oral semaglutide in higher doses based on the results Phase IIIb PIONEER PLUS study in patients with Type 2 diabetes.
Ticker: NVO
Executed On: Apr 04, 2023 at 10:00 AM EDT -
A look at the potential of oral semaglutide in higher doses based on the results Phase IIIb PIONEER PLUS study in patients with Type 2 diabetes.
Ticker: NVO
Executed On: Apr 04, 2023 at 07:00 AM EDT -
A third look: Discussing the use of Rybelsus(semaglutide) for adults with T2D as a first-line therapy
Ticker: NVO
Executed On: Jan 23, 2023 at 04:30 PM EST -
A second look: Discussing the use of Rybelsus(semaglutide) for adults with T2D as a first-line therapy
Ticker: NVO
Executed On: Jan 19, 2023 at 07:45 PM EST -
Discussing the use of Rybelsus(semaglutide) for adults with T2D as a first-line therapy
Ticker: NVO
Executed On: Jan 19, 2023 at 10:00 AM EST -
A third look at the potential of Icodec being investigated in the ONWARDS trial for treatment in patients with type 1 and type 2 diabetes
Ticker: NVO
Executed On: Nov 10, 2022 at 04:30 PM EST -
A third discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 03, 2022 at 11:30 AM EDT -
A second look at the potential of Icodec being investigated in the ONWARDS trial for treatment in patients with type 1 and type 2 diabetes
Ticker: NVO
Executed On: Nov 02, 2022 at 10:00 AM EDT -
A second discussion on the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Nov 01, 2022 at 03:00 PM EDT -
A Third Look: Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO
Executed On: Nov 01, 2022 at 02:00 PM EDT -
A discussion about managing patients with obesity and other overweight-related health problems. Focusing on the standard of care and the potential of Eli Lily's diabetes/weight loss drug, tirzepatide
Tickers: LLY, NVO
Executed On: Oct 31, 2022 at 03:30 PM EDT -
Discussing the NASH treatment landscape and the potential of Altimmune's phase 1 study of pemvidutide, a GLP-1/glucagon dual receptor agonist.
Tickers: ALT, LLY, NVO
Executed On: Oct 28, 2022 at 02:45 PM EDT -
A look at the potential of Icodec being investigated in the ONWARDS trial for treatment in patients with type 1 and type 2 diabetes
Ticker: NVO
Executed On: Oct 27, 2022 at 06:00 PM EDT -
A Second View: Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO, AZN
Executed On: Oct 20, 2022 at 09:30 AM EDT -
Understanding the Landscape of Type-2 Diabetes Treatments and the prevalence of Lilly's Mounjaro.
Tickers: LLY, NVO
Executed On: Oct 19, 2022 at 10:00 AM EDT -
A third look into therapies in development for Nonalcoholic steatohepatitis (NASH) including Semaglutide by Novo Nordisk
Ticker: NVO
Executed On: Aug 04, 2022 at 10:00 AM EDT -
A second look into therapies in development for Nonalcoholic steatohepatitis (NASH) including Semaglutide by Novo Nordisk
Ticker: NVO
Executed On: Jul 14, 2022 at 11:15 PM EDT -
A look into therapies in development for Nonalcoholic steatohepatitis (NASH) including Semaglutide by Novo Nordisk
Ticker: NVO
Executed On: Jul 14, 2022 at 06:30 PM EDT -
Another look at Tirzepatide, how it compares to semaglutide, and the potential in Type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 25, 2022 at 04:00 PM EDT -
A look at the upcoming PDUFA of tirzepatide and possible implications in Type 2 diabetes
Tickers: LLY, NVO
Executed On: Apr 21, 2022 at 03:00 PM EDT
Expired Projects (NVO)
-
A Third View: Discussing the risks of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide
Ticker: NVO
Scheduled For: Oct 31, 2024 at 10:30 AM EDT
Upcoming & Overdue Catalysts (NVO)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (NVO)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
